Navigation Links
ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4
Date:12/3/2008

    - Additional Pipeline Product Agreement Executed to Support ConjuChem's
      R&D Efforts -

MONTREAL and BAGSVAERD, Denmark, Dec. 3 /PRNewswire-FirstCall/ - ConjuChem Biotechnologies Inc. (TSX:CJB) and Novozymes Biopharma UK Ltd., a subsidiary of Novozymes A/S (LSE:NVZ) announced today that the Companies have entered into a long-term Manufacturing and Supply Agreement by which Novozymes Biopharma will exclusively supply its recombinant human albumin, Recombumin(R), for the continued development and commercialization of ConjuChem's PC-DAC(TM):Exendin-4. The Agreement calls for the initiation of additional capacity expansion of Novozymes Biopharma's Nottingham, England facility as well as additional expansion as global demand for PC-DAC(TM):Exendin-4 increases. The Agreement also allows ConjuChem to fully assign all rights to a PC-DAC(TM):Exendin-4 licensee.

In a separate Agreement, ConjuChem and Novozymes Biopharma entered into a Pipeline Product Agreement by which Novozymes Biopharma will also supply Recombumin(R) or other recombinant albumin products for the further development of ConjuChem's research and development product candidates.

Commenting on the Agreements, Mark Perrin, President & CEO of ConjuChem stated, "Recombumin(R) is an important part of our current technology and Novozymes Biopharma has been an integral partner in the development of our peptide conjugation platform. These two Agreements further solidify our relationship and are validation of the promise of our technology."

Peter Rosholm, Vice President of Novozymes Biopharma added, "This agreement allows Novozymes to demonstrate its commitment and capability to supply quality materials for use in biopharmaceutical manufacture and appropriate regulatory support on a long-term basis and thereby position itself as a reliable partner in this market."

About PC-DAC(TM):Exendin-4

Exendin-4, like Glucagon-like peptide-1 (GLP-1), is an agonist for the GLP-1 receptor. The clinical utility of native Exendin-4 is limited by its short half-life in plasma. Developed with ConjuChem's proprietary PC-DAC(TM) technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analog that is being developed for Type II diabetes. The Exendin-4 analog is covalently bound to recombinant human albumin (Recombumin(R), provided by Novozymes Biopharma). Data from Phase I/II clinical studies have demonstrated that the preformed albumin-peptide conjugate has a much longer half-life and efficacy than the peptide alone. The product is a highly soluble liquid formulation that is injectable in a small volume (less than or equal to 0.2ml) with a 31 gauge needle and is stable in pre-filled syringes at room temperature for a minimum of one month.

About Recombumin(R)

Recombumin is the world's first and only animal-free, commercially available recombinant human albumin approved for use in the manufacture of human therapeutics. Recombumin(R) offers the advantages of human serum albumin in a GMP, regulatory friendly package.

About ConjuChem

ConjuChem, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic PC-DAC(TM) Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide.

Detailed descriptions of the Company and its technologies can be viewed on the Company's website www.conjuchem.com.

About Novozymes and Novozymes Biopharma

Novozymes is the world leader in bio-innovations. Together with customers across a broad array of industries, the Company creates tomorrow's industrial bio-solutions, which both improves customers' business and the use of the planet's resources. Novozymes Biopharma is a world leader in yeast based protein expression, bringing over 20 years worth of experience in industrial scale recombinant protein production to the biopharmaceutical industry.

Detailed descriptions of the Company and its technologies can be viewed on the Company's website www.novozymes.com.

Forward-Looking Statements

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem's actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.


'/>"/>
SOURCE ConjuChem Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ConjuChem Provides Development Update
2. Novozymes Launches Enzyme to Reduce Acrylamide in Food
3. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
4. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
5. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
6. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
7. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
8. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
9. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
10. Neogen Acquires Kane Enterprises
11. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):